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Recent advances have shed light on the relationship between smooth muscle cell (SMC) phenotypic modulation, resolution 
of inflammation and atherosclerotic plaque stability. The thick fibrous cap covering the lipid core of plaques is composed of 
bundles of SMC and collagen fibers and few macrophages and lymphocytes, all of which make the plaque resistant to rupture. 
The thin fibrous cap contains many macrophages and lymphocytes, few SMC and less collagen fibers, all of which may weaken 
the cap, leaving the plaque vulnerable to rupture. In the present Dance Round, we, at a pharmacotherapeutic level, address the 
possibility of how the control over the activity of the essential cellular components of the plaque, particularly its fibrous cap, 
could be implicated in plaque stabilization, focusing on (i) the modulation of SMC from contractile to secretory (fibrogenic) 
phenotype, (ii) the control on plaque inflammation-resolution processes, and (iii) the reduction of plaque lipid content. Further 
studies on both unstable plaque and aortic aneurysm, which share a similar, matrix-based vulnerability, may bring new 
insights for pharmacotherapy of vascular injuries. Biomed Rev 2019; 30:136-141
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D a n c e  R o u n d WE DANCE ROUND IN A RING AND SUPPOSE,BUT THE SECRET SITS IN THE MIDDLE AND KNOWS.
ROBERT FROST
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The new paradigm should be not only different 
but also better.
Thomas S. Kuhn,  
The Structure of Scientific Revolutions, 1932
In 2017 Dance Round one of us together with his colleagues 
(1) described the following chronology in the ideogenesis of
atherosclerosis:
(i) during the 1960’s the great lady of atherosclerosis re-
search Maria Daria Haust proposed the first paradigm
shift in the field pointing to a new, synthetic versus
contractile function of the artery smooth muscle cells
(SMC);
(ii) in the 1970’s, we published the first transmission elec-
tron microscopic data of this new function conceptual-
izing it as “secretory function” instead of “synthetic
function” of SMC as has been previously considered
(reviewed in (2, 3);
(iii) in the 1980’s, atherosclerosis was rediscovered as an in-
flammatory disease (4);
(iv) in the 1990’s and 2000’s, the next paradigm shift has
emerged, namely from the inhibition of SMC prolifera-
tion (4) and secretion (5, 6) to the stimulation of these
same processes aimed at the plaque stabilization by in-
creasing fibrous cap thickness. Briefly, the increased se-
cretion of matrix molecules, particularly (pro)collagen,
by SMC could “shift” them from enemies to friends
in the fight against the unstable atherosclerotic plaque
(1, 7-9).
Yet, it is not clear why fibrous cap destruction takes place 
in macrophage-rich shoulder regions of the atherosclerotic 
plaque. Impaired cap formation caused by SMC senescence 
and/or proneness to apoptosis may also be critical in promot-
ing plaque rupture. 
In the present Dance Round, we, at a pharmacotherapeutic 
level, focus on the fibrous cap stabilization targeting (i) the 
stimulation of SMC secretory (fibrogenic) and proliferative 
activity, (ii) the inhibition of rupturogenic potential of mac-
rophages and lymphocytes, and (iii) the reduction of athero-
ma (plaque lipid core). The plaque regression, resulting in the 
overall reduction in plaque volume (10, 11), is out of scope of 
the present Dance Round. 
Of note, keeping in mind the importance of fibrous cap for 
the vulnerability of the plaque, we must proceed cautiously 
with the colchicine administration for cardiovascular diseas-
es (5, 12 and references therein), which antifibrotic action 
could decrease the thickness of fibrous cap making it vulner-
able to erosion and/or rupture. 
Atherosclerosis is a low-grate inflammatory disease char-
acterized by occlusion of large- and medium-sized arteries 
due to the formation of plaques (4). Plaque instability has 
been associated with erosion, ulceration or rupture of the 
fibrous cap that covers plaque lipid core. Recent advances 
have shed light on the relationship between SMC phenotypic 
modulation, inflammation-resolution and plaque vulnerabil-
ity-stability (14-17). 
FIBROUS CAP COMPOSITION
The thick fibrous cap covering the lipid core of atherosclerotic 
plaques is composed of bundles of SMC (and myofibroblasts?) 
and collagen fibers and few macrophages and lymphocytes. 
The thin fibrous cap contains many macrophages and lym-
phocytes, few SMC and less collagen fibers, all of which 
may weaken the cap, leaving the plaque vulnerable to rupture. 
This tends to occur in areas where the cap is the thinnest and 
most heavily infiltrated by macrophages. These are plaque 
shoulder region defined as the junction between the plaque 
and the adjacent, less diseased artery wall (Table 1, Fig. 1). 
In advanced atherosclerotic lesions calcification of the fibrous 
cap can develop.
Table 1. Major features of unstable atherosclerotic plaque
Thin fibrous cap (< 100 micrometer)
Increased presence of macrophages and lymphocytes
Low presence of SMC and collagen fibers
Large lipid core (> 30% of the total volume of plaque)
Presence of intraplaque hemorrhage
Cap erosion and thrombus formation
Increased expression of matrix degrading MMP
Reduced expression of tissue inhibitors of MMP (TIMP)
*SMC, smooth muscle cells; MMP, Matrix metalloproteinases
TIMP: Tissue inhibitors of metalloproteinases
To recap, the paradigm was shifted from the plaque size to 
the plaque stability, that is, the thickness of fibrous cap - the 
thicker the cap, the more stable the plaque. Accordingly, plaque 
stabilization has appeared as a promising therapeutic approach 
for the therapy of atherosclerosis (Fig. 2).
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molecular aspects of this phenomenon as related to plaque 
stability are not fully defined. Recently, it was demonstrated 
that a signaling cross-talk between fibroblast growth factor 
(FGF) and transforming growth factor-beta (TGF-β) in SMC 
plays an important role in the atherogenesis, namely, the in-
hibition of FGF signaling increases TGF-β activity, resulting 
in a significant increase of fibrous cap thickness and decrease 
of  lipid core size (18). 
Likewise, the critical role of SMC phenotypic modulation 
in aortic aneurysm and dissection in Marfan syndrome is inten-
sively studied (19-23). Note, both unstable (thin) fibrous cap 
and aortic aneurysm share a similar, matrix-based vulnerability.
Metalloproteinases inhibitors
Since metalloproteinases (MMP) favor matrix (collagen, 
elastin, and proteoglycans) degradation, the decrease of 
MMP activity may have a stabilizing action on the fibrous 
cap (24-27): In this vein, doxycycline, a MMP-2 and MMP-9 
inhibitor, significantly delays thoracic aorta aneurysm rupture 
in Marfan syndrome-like mice (19, 20). Because of the safety 
profile of the tetracyclines, clinical trials should be organized 
to determine if doxycycline could also delay the progression 
of plaque instability. Another MMP-related example is the 
phosphinic peptide (RXP470.1) which is a selective murine 
MMP-12 inhibitor (28).
Specialized pro-resolving mediators  
Defective resolution of inflammation is the underlying cause 
of various chronic inflammatory diseases, including athero-
sclerosis and other cardiometabolic diseases. Inflammation-
resolution are active processes aimed at restoration of tis-
sue integrity and function. These are governed in part by 
endogenously synthesized pro-resolving mediators, such as 
lipoxins, resolvins, protectins, and maresins. Compromised 
inflammation-resolution is an important driving force in the 
progression of atherosclerosis and, respectively, a promis-
ing pharmacological target for its therapy (29). In effect, the 
“resolution pharmacology” might be a therapeutic option for 
atherosclerosis (30).
Omega-3 essential fatty acids serve as substrates for the 
formation of a group of lipid-derived mediators that partici-
pate in the resolution of inflammation. Among them, the ei-
cosapentaenoic acid (EPA)-derived resolvin E1 appears to be 
of particular interest, as dietary supplemented EPA was found 
to preferentially be distributed in thin fibrous cap, implying 
an important plaque stabilizing potential (31). The direct re-
Figure 1. A drawing illustrating the composition of unstable 
and stable atherosclerotic plaque and its possible reversibility 
(two arrows). Both plaques are covered by single layer of en-
dothelial cells (green) and fibrous caps (red). Unstable plaque 
has thin fibrous cap containing macrophages (blue granules) 
and few smooth muscle cells (SMC) (blue spindles), which 
may weaken the cap, leaving it vulnerable to rupture (white 
lines in cap’s shoulder (at right). In contrary, stable plaque 
has thick fibrous cap composed of many SMC (blue spindles) 
and few macrophages (blue granules). Within the plaque, 
lipid core (yellow) is larger in unstable than in stable plaque, 
whereas macrophages and lymphocytes (blue granules) are 
more in unstable than in stable plaque. In unstable plaque, two 
intraplaque hemorrhages (red) are also depicted. From (13), 
a colored version of these latter authors’ Figure 1. 
Figure 2. An illustration of the paradigm shift in the process 
of atherogenesis (long arrow), SMC, smooth muscle cells. 
From (13).
FACTORS INVOLVED IN PLAQUE STABILIZATION 
Possible ways for the stabilization of fibrous cap might be: (i) 
making the cap more fibrous, (ii) attenuating inflammation, 
stimulating the resolution of inflammation, and (iii) reducing 
plaque lipid content. 
Phenotypic modulation of SMC
Traditionally, the conversion from contractile to secretory 
phenotype of SMC was thought to play a pivotal role in 
the pathobiology of atherosclerosis (1, 4-6). However, the 
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petitive delivery of pro-resolving mediators themselves also 
suggests a potentially innovative strategy for resolving ar-
terial inflammation. The systemic administration of resolvin 
D2 and maresin 1 has been shown in a mice model of athero-
progression to prevent the expansion of the necrotic core and 
the accumulation of macrophages, simultaneously increasing 
the number of SMC and the fibrous cap thickness (32).
Acetylcholine anti-inflammatory pathway
The cholinergic anti-inflammatory pathway is dependent on 
the nicotinic acetylcholine receptor α7 subunit. Accordingly, 
selective acetylcholine receptor α7 agonists reduce the level 
of pro-inflammatory mediators (e.g. TNF-alpha) in experi-
mental models of inflammatory disease (33). Notably, as re-
ported by Rosso et al in this volume of Biomedical Reviews, 
vagus nerve stimulation leads to the increased expression of 
nerve growth factor (NGF), the latter being also a subject of 
discussion in the present Dance Round (see next section and 
Table 2),
Further studies on the cholinergic anti-inflammatory 
mechanisms may provide new insights for the pathogenesis 
and therapy of atherosclerosis.
Nerve growth factor
In addition to platelet-derived growth factor, FGF and other 
fibrogenic factors (for galectin-3 see Kisheva and Yotov in 
this volume of Biomedical Reviews), recent studies have 
demonstrated that nerve growth factor (NGF) has effects on 
myofibroblasts and  collagen synthesis, and, respectively, 
fibrotic disorders (34, 35). 
Keeping in mind that (i) atherosclerotic plaque may be 
viewed as a vascular wound (1, 4), (ii) topical application 
of NGF expresses healing effects on corneal ulcers, diabetic 
wounds, pressure ulcers, and chronic vasculitic ulcers (36-38), 
and (iii) reduced local and circulating level of NGF was found 
in human coronary atherosclerosis and metabolic syndrome 
(39), we suggest that NGF may also demonstrate healing effect 
on atherosclerotic plaque (vascular wound).
Noteworthy, Professor Russell Ross (1929-1999), the 
author of more than 300 peer-reviewed papers including the 
seminal review cited herein (4), has started his research career 
on cell biology of skin wound before became one of the most 
renowned scientists in the field of atherosclerosis.
A summing-up list of agents with potentials for plaque 
stabilization is shown in Table 2.
Table 2. Selected list of possible plaque stabilizers
• Stimulators of matrix molecule secretion by smooth muscle 
cells (SMC)*
• Matrix metalloproteinases-targeting agents
o Inhibitors of matrix metalloproteinases
o Activators of tissue inhibitors of metalloproteinases
• Inflammation-targeting agents
o Inhibitors of inflammation
o Stimulators of resolution of inflammation
• Acetycholine-targeting agents
o Nicotinic acetylcholine receptor α7 agonists
• Lipid-targeting agents
o Inhibitors of phosphatidylcholine phospholipase C (40)
–  The xanthate selective inhibitor D609 (41); new selec-
tive inhibitors (chiral derivatives of tetrahydrobenzo-
oxazepines) (42)
o Inhibitors of sphingomyelin synthase 2
–  D609 (43); Ly93 (2-benzyloxybenzamides analog) (44)
o Statins (10)
o PCSK-9 (pro-protein convertase subtilisin/kexin type 9) 
inhibitors: evolocumab, alirocumab (45, 46)
• NGF and TrkANGF receptor agonists (3)
* For SMC apoptosis and proliferation, also lipids, see Fig. 2. For 
decrease of macrophage proliferation, see (47).
EPILOGUE
Rapidly accelerating knowledge and continued research 
promise to provide further progress in the prevention and 
therapy of cardiovascular disease. Atherosclerotic plaque 
is like a volcano that sleeps - if it erupts, its lava stops the 
blood flow and the oxygen-deprived heart becomes numb - 
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